Business Context and Reporting Period
This Form 8-K is filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on August 4, 2023. The report primarily addresses a change in executive leadership and references the company's financial results for the three and six months ended June 30, 2023, which were announced via a press release on August 10, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the press release (Exhibit 99.1) referenced in Item 2.02 but are not detailed within the body of this 8-K document.
Material Changes
- Executive Appointment: On August 4, 2023, James Liu was promoted to Senior Director, Controller & Principal Accounting Officer.
- Interim CFO Role: James Liu was simultaneously appointed as interim Principal Financial Officer (CFO) to serve until a permanent Chief Financial Officer is appointed.
- Compensation: Mr. Liu's annual salary is set at $200,000 with a target discretionary bonus of 35% of his base salary. No additional compensation is provided for the interim CFO role.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future performance, or a detailed discussion of risks and contingencies. It notes that the financial results referenced in Item 2.02 are furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting their legal liability status.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) for the period ended June 30, 2023, by reviewing the press release dated August 10, 2023 (Exhibit 99.1).
- Confirm the timeline for the appointment of a permanent Chief Financial Officer to replace the interim appointee.
- Review the company's cash runway and liquidity status given the recent leadership transition in the finance department.